Biotech Industry · global
Pfizer’s Monthly Weight-Loss Drug Secures Up to $1.5 Billion in R&D Funding, With Blackstone’s Returns Tied to Approval and Sales
Blackstone will share berobenatide’s development costs through 2028, while Pfizer retains rights to the drug and decision-making authority. The funding supports a program encompassing 10 ongoing or planned Phase 3 trials, but the efficacy and safety of once-monthly injections still require clinical evidence.
A once-monthly injectable weight-loss treatment must still clear large-scale trials and regulatory review before reaching clinical practice. Pfizer announced on November 11 that it had reached a co-funding agreement with Blackstone Life Sciences. Funds managed by Blackstone will cover up to $1.5 billion in research and development expenses to support the development of the drug candidate berobenatide through 2028, providing funding for this long-acting therapy.
The deal ties Blackstone’s potential returns to the drug’s subsequent outcomes. According to the parties’ announcements, payment conditions involve U.S. approval of once-monthly berobenatide as a standalone treatment for chronic weight management, as well as the achievement of specified commercial sales milestones. If the conditions are met, the related payments will be made over multiple years. The announcements did not disclose the milestone payment amounts or sales thresholds; $1.5 billion is the cap on R&D funding.
Blackstone will not acquire rights to or ownership of berobenatide through this agreement. Pfizer will retain full operational control and decision-making authority over the program. Blackstone’s perpetual private equity strategy, BXPE, will also invest alongside its life sciences funds. Under the agreement, Pfizer can bring in external funding to share development expenses while retaining control over the program’s future direction.
Berobenatide is an investigational GLP-1 receptor agonist peptide being developed for chronic weight management and obesity-related comorbidities. Pfizer said the drug has a total of 10 ongoing or planned Phase 3 trials, with research covering knee osteoarthritis and obstructive sleep apnea. This figure includes studies still in planning and should not be interpreted as meaning that all 10 trials have begun.
Pfizer also plans to explore combinations of berobenatide with other peptides, including amylin analogs. However, the approval condition governing Blackstone’s returns explicitly concerns once-monthly use as a standalone treatment for weight management and cannot be directly extended to all combination therapies or comorbidity indications.
Goodwin, the law firm representing Blackstone in the transaction, separately confirmed on November 12 that its Life Sciences Royalty Finance team provided legal services for the deal. It also reiterated the funding cap, timeframe, and return arrangements tied to approval and sales. This confirmation added transaction information but provided no additional evidence of the drug’s efficacy.
The announcement provided no new data on the magnitude of weight loss, discontinuation rates, or long-term safety, nor did it list readout timelines for the individual Phase 3 trials. If once-monthly dosing proves viable, it could reduce the number of injections. Whether it can maintain efficacy and improve treatment persistence still requires validation in trials. The funding provides stronger support for the development program, but whether the drug ultimately becomes an available treatment option still depends on clinical results and regulatory review.